Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

https://otc.duke.edu/wp-content/uploads/2022/08/precision-biosciences-building.jpg

Precision BioSciences Opens New Manufacturing Facility in Durham

Precision BioSciences, a genome-editing company based in Durham, announced today the opening of its highly prized production facility for in-house manufacturing of its unique technologies. Calling it the Manufacturing Center for Advanced Therapeutics (MCAT), Precision…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/DMClogo-Final-1.png

DMC Bio, Inc. Announces First Close of $10.3M Series A Financing Led by Sofinnova Partners

DMC, an early-stage biotechnology company, announced today that is has raised a Series A equity financing led by Sofinnova Partners. The company also announced the addition to its Board of Directors of Josko Bobanovic, Partner…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/gie-logo-0908bcad55e5147a4f4d2af945b13ceaec51d30ee5122ecf9c92db157b945eb2.png

DIV Update: Pocket Colposcope

Nearly 300,000 women die of cervical cancer in low- and middle-income countries, about 85 percent of worldwide deaths from this disease. Early detection and treatment can prevent up to 80 percent of these cancers when…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/phasebio-logo.png

PhaseBio: Positive Results from Phase 2a Clinical Trial of PB2452

PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects   June 17, 2019 16:01 ET | Source: PhaseBio…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/LumedicaJuly2019-1.jpg

Lumedica looks to fine-tune low-cost OCT system with SBIR grant

Duke University spin-out wins Phase II funding to further develop device for clinical applications in low-resource settings. Lumedica, the startup company spun out of co-founder Adam Wax’s Duke University research group, has won a $1 million…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/Adam-Wax_2019-1.jpg

A Conversation with Lumedica’s Adam Wax

Late last month, Luminate—a Rochester, N.Y.–based startup accelerator focusing on optics, photonics and imaging technologies—announced the winners of its second-round accelerator competition. Taking third place, and taking home a cool US$250,000 of seed money from…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/LWhaRIM.png

“Deep Sepsis” Licensed to Cohere Med

Cohere Med licenses technology from Duke to drive adoption of early Sepsis detection using AI   PRESS RELEASE: 3 JULY 2019 Sepsis strikes more than a million Americans every year and 15 to 30 percent…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/Phitonex_Launches_NovaFluor_Dyes_Enabling-a612362d1c9ce0cc2111789465717fd3-1.jpg

Phitonex Launches NovaFluor Dyes Enabling High-Res Analysis

Phitonex, Inc. launched their new suite of NovaFluor dyes today at CYTO2019, the 34th Congress of the International Society for Advancement of Cytometry, the largest industry conference in single cell biology. New dyes developed on…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/Enzyvant_Logo_7699_RGB_-1.jpg

Enzyvant Announces FDA Acceptance of Biologics License Application

Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia CAMBRIDGE, Mass. & BASEL, Switzerland–(BUSINESS WIRE)–Enzyvant, a biopharmaceutical company focused…

Read More